BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 17512453)

  • 1. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonates and breast cancer].
    Vehmanen L; Saarto T
    Duodecim; 2010; 126(10):1229-37. PubMed ID: 20597352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
    Diel I; Aebi S
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
    [No Abstract]   [Full Text] [Related]  

  • 10. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of bisphosphonates in cancer patients.
    Wu S; Dahut WL; Gulley JL
    Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular basis of bone metastasis formation and its targeted therapy].
    Tímár J
    Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of bisphosphonates in early breast cancer.
    Paterson AH
    Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in breast cancer: antitumor effects.
    Aft R
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
    Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
    Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
    Clemons M; Dranitsaris G; Cole D; Gainford MC
    Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.